Delcath Systems (DCTH) is an interventional oncology company focused on the treatment of primary and metastatic liver cancers.
Employees: 11-50
Total raised: $33.8M
Founded date: 1988
Investors 1
| Date | Name | Website |
| - | Centrecour... | centrecour... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 26.08.2010 | - | $33.8M | - |
Mentions in press and media 16
| Date | Title | Description |
| 11.09.2025 | Jason Chambers Headlines the Melanoma Research Foundation's 24th Annual New York Gala | Jason Chambers Headlines as Emcee of the 24th Annual New York Gala The Melanoma Research Foundation (MRF) will host its 24th Annual New York City Gala on Thursday, October 30 at Cipriani Broadway. This inspirational event honors those in th... |
| 07.05.2024 | Delcath Systems to Host First Quarter 2024 Earnings Call | QUEENSBURY, N.Y., May 7, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call o... |
| 30.03.2023 | Delcath Systems Announces Closing of Private Placement of up to $85 Million | Led by Vivo Capital with participation from Logos Capital, BVF Partners LP, Stonepine Capital Management, LLC, Serrado Capital LLC and supported by existing investor, Rosalind Advisors $25 million financing upfront with up to an additional ... |
| 28.03.2023 | Delcath Systems To Raise Up To $85M Financing | Delcath Systems, Inc. (Nasdaq: DCTH), a NYC-based interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, signed securities purchase agreements with certain healthcare-focused institutional i... |
| 04.10.2022 | ROTH Capital Partners to Host Inaugural Healthcare Opportunities Conference on October 6th at the Yale Club in New York City | Event to feature company presentations and one-on-one meetings between institutional investors and senior management from select Healthcare companies in Biotechnology, Pharmaceuticals, Medical Technologies, Oncology and Mental Health Therap... |
| 09.08.2021 | Delcath Systems Secures Up to a $20.0 Million Debt Facility with Avenue Venture Opportunities Fund, L.P. | NEW YORK, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today that it has entered into a de... |
| 09.08.2021 | Delcath Systems Secures Up to A $20.0 Million Debt Facility with Avenue Venture Opportunities Fund, L.P | Delcath Systems, Inc. announced that it has entered into a debt facility with Avenue Venture Opportunities Fund, L.P. ("Avenue Venture Fund") providing up to $20 million with an initial $15 million funded at close. Additional deta... |
| 19.12.2014 | Delcath expands Phase II trial | Delcath Systems (NSDQ:DCTH) said it added 2 German research centers to a global Phase II trial of its Chemosat melphalan hepatic delivery system in treating primary liver cancer. The 2 facilities, Hannover Medical School Hospital and Jena U... |
| 23.10.2013 | Troubled Delcath announces $7.5M offering, drops 23% | New York’s Delcath Systems (NSDQ:DCTH) is looking to raise about $7.5 million through sales of common stock, planning on using the funds for working capital, commercialization efforts, clinical trials and other "general corporate purpo... |
| 03.05.2013 | Delcath plunges after FDA panel recommends against liver cancer treatment approval | Shares of Delcath (NSDQ:DCTH) have lost nearly half their value so far today after an FDA panel recommended against approval for its liver cancer treatment. The FDA’s Oncologic Drugs Advisory Committee voted 16-0 that the risks associated w... |
Show more